Monday, March 20, 2017
Array Biopharma provides NEMO update. Array Biopharma Inc - Has withdrawn from U.S. FDA division of oncology products 2 its new drug application (NDA) for binimetinib monotherapy.
Says ongoing clinical trials for binimetinib will continue.
Array Biopharma Inc - Withdrawl will not impact planned Phase 3 columbus trial NDA of binimetinib.
